Cerebral Artery Syndrome Treatment Market Analysis

  • Report ID: 3463
  • Published Date: Nov 19, 2025
  • Report Format: PDF, PPT

Cerebral Artery Syndrome Treatment Market Segmentation:

Surgery Type Segment Analysis

Cerebral artery syndrome treatment market for the carotid endarterectomy segment is anticipated to hold the largest share of 43% during the forecast period. As it lowers the risk of stroke, carotid endarterectomy is a surgical technique that is becoming more and more common. Therefore, the increasing number of cases of stroke is propelling the growth of the segment. The high success rate of this method is the primary cause of the tremendous growth. Additionally, this sort of surgery is widely accessible, which promotes the growth of this market. The procedure's increased demand has also been attributed to improvements in safety and effectiveness brought about by medical technological breakthroughs.

Distribution Channel Segment Analysis

The hospital segment in the cerebral artery syndrome treatment market is expected to hold a share of 50% during the foreseen period. The growth can be attributed to the growing number of patients globally. Also, the presence of a large number of hospitals providing advanced healthcare services. Hospitals have higher acceptance amongst the public, which is estimated to boost market growth. Additionally, hospitals often have dedicated stroke units and rehabilitation services, which are crucial for managing and recovering from cerebral artery syndrome.

Our in-depth analysis of the global market includes the following segments:

Treatment

  • Surgery
  • Medication

Surgery Type

  • Carotid Endarterectomy
  • Angioplasty
  • Bypass Surgery

Distribution Channel

  • Hospital
  • Specialty Clinic
  • Online Pharmacies

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of cerebral artery syndrome treatment is estimated at USD 2.37 billion.

The global cerebral artery syndrome treatment market size crossed USD 2.24 billion in 2025 and is likely to register a CAGR of over 6.3%, exceeding USD 4.13 billion revenue by 2035.

North America is set to account for the largest revenue share of 35% by 2035, driven by rising awareness of minimally invasive stroke treatments and increasing prevalence of atrial fibrillation.

Key players in the market include Bristol Myers Squibb, Athersys, Inc., Janssen Pharmaceuticals, Inc, Royal Philips, AstraZeneca plc, Daiichi Sankyo Company, Limited, LIFESCAPES Inc, Shionogi & Co., Ltd., Fujitsu, Takeda Pharmaceutical Co Ltd.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos